In a head-to-head comparison of two multi-gene breast cancer recurrence tests, Genomic Health's Oncotype DX and Agendia's MammaPrint yielded divergent results.

The study, led by researchers from Genomic Health and L’Institut du Sein at the Paris Breast Center, found that Oncotype DX identified a lower number of breast cancer patients as being at high risk of recurrence than did MammaPrint. The researchers presented the results at the San Antonio Breast Cancer Symposium held earlier this month.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.